Novel patient-derived tongue squamous cell carcinoma cell lines from non-smokers: 3D and in vivo models for drug response studies.

Authors

Graziella Ribeiro de Sousa, Guilherme da Silva Carvalho, Bruna Miyoko Ikenaga de Brito, Gabriel da Silva, Maria Clara Rezende Barbosa Lopes, Pablo Shimaoka Chagas, Elvis Terci Valera, Graziela Vieira Cavalcanti, Luiz Carlos Conti de Freitas, Andréia Machado Leopoldino

Published in

Medical oncology (Northwood, London, England). Volume 43. Issue 8. Jun 29, 2026. Epub Jun 29, 2026.

Abstract

Tongue squamous cell carcinoma (TSCC) is the most prevalent and aggressive subtype of oral squamous cell carcinoma (OSCC), with a high incidence of lymph node metastasis even in early stages. The five-year overall survival rates remain low, around 50% in advanced stages. Cell line models are essential tools to understand the complexity of TSCC and develop new therapies. However, most commercially available TSCC cell lines are derived from patients with a history of tobacco use or have unknown exposure backgrounds. We established two novel TSCC cell lines, LMSCC03 and LMSCC16, derived from non-smoking and treatment naïve Brazilian patients. These cell lines were characterized by doubling time, 3D culture (spheroids and organoids), tumorigenicity through xenotransplantation in nude mice, immunohistochemical expression of key OSCC biomarkers and drug response. Genetic identity was confirmed by STR profiling. LMSCC03 and LMSCC16 displayed epithelial morphology and pan-cytokeratin staining. They demonstrated in vitro capacity to form spheroids and organoids, and generated tumors in vivo. STR profiling confirmed their novelty relative to existing cell lines in the DSMZ database. Protein analysis revealed high p53 nuclear levels in LMSCC16 cells. Interestingly, CD44 and c-Myc expression were observed only in fibroblast-enriched cultures, but not in the epithelial LMSCC03 and LMSCC16 cells. LMSCC16 also harbored two TP53 mutations and showed increased resistance to Cisplatin and Paclitaxel compared to established TSCC cell lines. Cisplatin treatment in spheroids reduced OCT4, CCND1, CCNB1, and CDH1 gene expression in LMSCC03. In contrast, LMSCC16 showed significant modulation of OCT4, increased CCND1 and CCNB1 expression, and reduced CDH1 levels following treatment. We established two novel TSCC cell lines that represent clinically relevant models to explore TSCC carcinogenesis and therapeutic responses, particularly in non-smoking populations.

PMID:
42371352
Bibliographic data and abstract were imported from PubMed on 29 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.